ReviewActa pharmaceutica Sinica. B2026
From concept to application: Exploring the evolution and potential of DUBTAC technology.
Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The role of deubiquitinating enzymes and their inhibitors in esophageal carcinoma (Review).International journal of oncology · 2026Review
- Deubiquitinating enzymes in cervical cancer: Molecular mechanisms and therapeutic implications (Review).International journal of oncology · 2026Review
- Fine-Tuning Protein Fate: Mechanisms of E1, E2, and E3 Enzymes and Deubiquitinases in Cell Signaling.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deubiquitinase-targeting chimeras (DUBTAC), as a highly promising emerging technology, can precisely remove ubiquitin chains from target proteins by recruiting deubiquitinases (DUBs), thereby enhancing the stability of the target proteins. Multiple functional proteins, such as the tumor suppressor proteins p53, RB, PTEN, upon stabilization by DUBTAC, can effectively restore or enhance their physiological functions, thus achieving therapeutic effects. Currently, the DUBTAC technology is still in its early stage of development, yet it has broad application prospects and represents a technological approach for developing various "undruggable" targets. This article delves into the design strategy of DUBTAC, and screens and recommends some candidate proteins with the potential to serve as drug targets. We aim to provide perspective in drug design, structural optimization, target selection, and related aspects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.